"10.1371_journal.pone.0141771","plos one","2015-11-06T00:00:00Z","Rahul A Jonas; Ya Xing Wang; Hua Yang; Jian Jun Li; Liang Xu; Songhomitra Panda-Jonas; Jost B Jonas","Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Science Key Lab, Beijing, China; Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University of Heidelberg, Mannheim, Germany","Conceived and designed the experiments: RAJ YXW HY JJL LX SPJ JBJ. Performed the experiments: RAJ YXW HY JJL LX SPJ JBJ. Analyzed the data: RAJ YXW SPJ JBJ. Contributed reagents/materials/analysis tools: LX JBJ. Wrote the paper: RAJ YXW HY JJL LX SPJ JBJ.","Jost B. Jonas: Consultant for Allergan Inc.; Merck Sharp & Dohme Co., Inc.; Alimera Co.; Boehringer Ingelheim Co., Sanofi Co.; Patent holder with Biocompatible UK Ltd. (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and patent application with university of Heidelberg (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4). Songhomitra Panda-Jonas: Patent holder with Biocompatible UK Ltd. (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and patent application with university of Heidelberg (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europäische Patentanmeldung 15 000 771.4). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. All other authors have no conflicts of interests to declare.","2015","11","Rahul A Jonas","RAJ",7,TRUE,7,7,4,7,TRUE,TRUE,FALSE,0,NA,FALSE
